GH Guardant Corp Expected net earnings per share growth this year

Official company branding of guardanthealth.com (GH)

By recruiting leading bioinformaticians and molecular biologists, Guardant Health, Inc. (GH) has expanded its R&D potential. The annual net income per share trend reflects the current market consensus, while -1.90 marks a new level. Looking ahead, the company aims for expansion driven by FDA-approved liquid biopsy tests and aggressive management investment in clinical trials to achieve profitability.

GH Guardant360 Earnings per share growth in current year (07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Guardant Health, Inc. (GH)

- stock value and consensus price forecast:
Market Price Guardant Health Inc|GH - Price Target Chart
- market capitalization data:
Market Capitalization Guardant Corp|GH - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Guardant Health|GH - Company Book Value|Market Capitalization to Book Value guardanthealth.com|GH - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Ratio Guardant Health, Inc.|GH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital guardanthealth.com|GH - Company Aggregate Debts|Debts to Book Capitalization Guardant Corp|GH - Company Long-Term Debt|Company Short-Term Loans and Borrowings Guardant Health|Immediate Liquidity Ratio guardanthealth.com
- earnings and multiples data:
GH - Net Profit|Projected Future Earnings Guardant Health, Inc.|GH - Price to Earnings Ratio|Price to Future Earnings Ratio Guardant Corp|GH - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Guardant Corp|GH - Operating profit before deduction of amortization|Earnings per share for the trailing year Guardant Health|GH - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months guardanthealth.com|GH - Earnings growth in current year|Expected net earnings per share growth next year Guardant Health, Inc.
- revenue and sales proceeds data:
GH - Revenue and Sales Volume
Fundamental valuation:Guardant Health, Inc.
Original product of Guardant Health, Inc.

For Guardant Health, Inc. (GH), outsourcing sequencer production and cloud computing directly impacts the annual growth rate of net earnings per share by optimizing capital expenditures. This indicator captures the percentage shift in earnings per share relative to the previous year, isolating fundamental business growth from market volatility, which allows investors to assess the real efficiency of the operating model and the asset's resilience.

Main competitors

Earnings per share growth rate in current year Caris Life Sciences Inc (CAI)|Earnings per share growth in current year Veracyte Corp|Celcuity Therapeutics (CELC) - Expected net earnings per share growth this year|Earnings growth in current year GRAL|Expected net earnings per share growth this year myriad.com|Earnings per share growth in current year Castle Biosciences, Inc. CSTL|Expected net earnings per share growth this year Burning Rock Biotech Limited (BNR)|VolitionRx Ltd - Earnings growth in current year|Net earnings per share change in current year Biodesix Corporation (BDSX)|PRPO (Precipio, Inc.) - Net earnings per share growth this year|Check-Cap (CHEK) - Earnings growth in current year|MYNZ (Mainz Biomed) - Earnings growth in current year|Earnings growth in current year OncoCyte Corp